MIP's Charlotte Kilpatrick talks to  Corey Salsberg of Novartis, Ellen t’Hoen of Medicines Law and Policy, and David Rosenberg formerly of GSK to discuss how COVID-19 is reshaping IP in the life sciences. episode artwork

EPISODE · Jun 24, 2020 · 48 MIN

MIP's Charlotte Kilpatrick talks to Corey Salsberg of Novartis, Ellen t’Hoen of Medicines Law and Policy, and David Rosenberg formerly of GSK to discuss how COVID-19 is reshaping IP in the life sciences.

from MIP podcasts · host MIP

Charlotte Kilpatrick, reporter at Managing IP, sat down with Corey Salsberg of Novartis, Ellen t’Hoen of Medicines Law and Policy, and David Rosenberg formerly of GSK, to discuss how COVID-19 is reshaping the IP landscape in the life sciences industries. The guests debated IP issues including access to medicine, open science, and the role patent and technology pooling can play to accelerate vaccine research.

Episode metadata supplied by the publisher feed · Published Jun 24, 2020

Embed this episode

Ready to play

MIP's Charlotte Kilpatrick talks to Corey Salsberg of Novartis, Ellen t’Hoen of Medicines Law and Policy, and David Rosenberg formerly of GSK to discuss how COVID-19 is reshaping IP in the life sciences.

0:00 48:16

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

Frequently Asked Questions

How long is this episode of MIP podcasts?

This episode is 48 minutes long.

When was this MIP podcasts episode published?

This episode was published on June 24, 2020.

Can I download this MIP podcasts episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!